Skip to main content
. 2021 Aug 2;12(8):761. doi: 10.1038/s41419-021-04055-2

Fig. 3. PLA upregulates FGFBP1 expression through activation of mTORC1.

Fig. 3

A, B NCI-H292 (A) and BEAS-2B (B) cells were pretreated with PLA (20 μg/mL, 12 h) before rapamycin (50 nM, 12 h) treatment. C NCI-H292 cells were transfected with siRNA targeting mTOR (simTOR), Raptor (siRaptor), or the control (siNC) for 48 h before PLA (20 μg/mL, 12 h) treatment. D NCI-H292/shRictor or NCI-H292/shSc cells were treated with PLA (20 μg/mL) for 24 h. E BEAS-2B/shRaptor or BEAS-2B/shSc cells were treated with PLA (20 μg/mL) for 24 h. F Tsc1+/+ and Tsc1−/− MEFs. G Tsc2+/+ and Tsc2−/− MEFs. A–G All cell lysates were collected for western blot with the indicated antibodies (A, B, F, and G, left panels and C–E, upper panels) and FGFBP1 mRNA was detected by qRT-PCR (A, B, F, and G, right panels and C–E, lower panels). Results are shown as mean ± SD from three independent experiments. **P < 0.01; ***P < 0.001; ****P < 0.0001; NS not significant.